SCHEMBL4174879

SCHEMBL4174879

CNC(=O)c1cc(Cl)c(OCc2ccc(OC)cc2)cc1OC[C@H]1CO1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.47
KDM4E B2RXH2 3/20 0.47
CYP1A2 P05177 2/20 0.47
CYP2C9 P11712 2/20 0.47
CYP2C19 P33261 2/20 0.47
LMNA P02545 2/20 0.43
POLB P06746 2/20 0.43
CYP3A4 P08684 1/20 0.43
PKM P14618 1/20 0.41
MAPT P10636 2/20 0.41
MEN1 O00255 1/20 0.41
GAA P10253 1/20 0.41
KMT2A Q03164 1/20 0.41
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
PDE4A P27815 1/20 0.40
PDE4B Q07343 1/20 0.40
PDE4C Q08493 1/20 0.40
PDE4D Q08499 1/20 0.40
CASP3 P42574 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3932510 1.00 ALDH1A1 (0.47) ALDH1A1KDM4ECYP1A2CYP2C9CYP2C19
SCHEMBL1787083 0.91 ALDH1A1 (0.48) ALDH1A1KDM4ECYP1A2CYP2C9CYP2C19
SCHEMBL4189521 0.90 ALDH1A1 (0.46) ALDH1A1KDM4ECYP1A2CYP2C9CYP2C19
SCHEMBL4177944 0.87 KDM4E (0.44) ALDH1A1KDM4ECYP1A2CYP2C9CYP2C19
SCHEMBL4555820 0.87 KDM4E (0.44) ALDH1A1KDM4ECYP1A2CYP2C9CYP2C19
SCHEMBL4751869 0.86 ALDH1A1 (0.43) ALDH1A1KDM4ECYP1A2CYP2C9CYP2C19
SCHEMBL4222778 0.85 SMPD1 (0.46) ALDH1A1KDM4ELMNAPOLBPKM
SCHEMBL4191981 0.84 ALDH1A1 (0.52) ALDH1A1KDM4ECYP1A2CYP2C9CYP2C19
SCHEMBL4754155 0.83 ALDH1A1 (0.52) ALDH1A1KDM4ECYP1A2CYP2C9CYP2C19
SCHEMBL3933561 0.82 ALDH1A1 (0.53) ALDH1A1KDM4ECYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090176815-A1 Novel Tricyclic Spiropiperidine Compounds, Their Synthesis and Their Uses as Modulators of Chemokine Receptor Activity ASTRAZENECA AB (SE) 2009-07-09 US disclosed
US-20080167332-A1 Novel Compounds 243 ASTRAZENECA AB (SE) 2008-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167332-A1 Novel Compounds 243 UGT1A10, ABCG2, VKORC1L1 ALDH1A1 407/4885KDM4E 2805/4885CYP1A2 45/4885
US-20090176815-A1 Novel Tricyclic Spiropiperidine Compounds, Their Synthesis and Their Uses as Modulators of Chemokine Receptor Activity ACKR3, CCR2, CCR5 ALDH1A1 648/4885KDM4E 4622/4885CYP1A2 998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.